Progress in the last decade has improved the understanding of leukemia biology. Molecular
markers in combinations with cytogenetics have improved the risk stratification of acute …

BACKGROUND. It is unknown whether patients with nonleukemic myeloid sarcoma (MS)
and those with acute myeloid leukemia (AML) have similar responses to anti‐AML treatment …

Treatment of older adults with acute myeloid leukemia (AML) or myelodysplastic syndromes
(MDS) is challenging because of disease morbidity and associated treatments. Both …

This report investigated the impact of graft-versus-host disease (GVHD) on transplantation
outcomes in 1859 acute myeloid leukemia patients given allogeneic peripheral blood stem …

The majority of patients with acute myeloid leukaemia (AML) are elderly. Advancements in
supportive care and regimen intensification have resulted in improvements in clinical …

Acute myeloid leukaemia (AML) is a heterogeneous disease that is, in general, associated
with a very poor prognosis. Multiple cytogenetic and molecular abnormalities that …

Background: Acute myeloid leukemia (AML) is a clonal disease characterized by the
proliferation and accumulation of myeloid progenitor cells in the bone marrow, which …

Epigenetic changes have been identified in recent years as important factors in the
pathogenesis of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) …

Abstract Acute Myeloid Leukemia (AML) has a median age at diagnosis of 67 years. The
most common curative therapy remains an allogeneic hematopoietic stem cell …

Allogeneic stem cell transplantation with HLA-matched donors is increasingly used for older
patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It …